MARKSANS PHARMA
Back to Balance Sheet
|
MARKSANS PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | - | ₹1.45 Cr | ₹1.45 Cr | ₹20 Cr | ₹48 Cr |
What is the latest Contingent Liabilities ratio of MARKSANS PHARMA ?
Year | Contingent Liabilities |
---|---|
Mar2024 | - |
Mar2023 | ₹1.45 Cr |
Mar2022 | ₹1.45 Cr |
Mar2021 | ₹20 Cr |
Mar2020 | ₹48 Cr |
How is Contingent Liabilities of MARKSANS PHARMA Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | - | -100.00 | |
Mar2023 | ₹1.45 Cr | 0.00 | |
Mar2022 | ₹1.45 Cr | -92.68 | |
Mar2021 | ₹20 Cr | -58.94 | |
Mar2020 | ₹48 Cr | - |
Compare Contingent Liabilities of peers of MARKSANS PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MARKSANS PHARMA | ₹10,915.3 Cr | -4.8% | -21% | 64.4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹418,744.0 Cr | -4.2% | -7.7% | 24.1% | Stock Analytics | |
DIVIS LABORATORIES | ₹152,209.0 Cr | -0.6% | -5.6% | 57.5% | Stock Analytics | |
CIPLA | ₹117,762.0 Cr | 3.3% | -4.8% | 6.5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,705.3 Cr | -2.4% | -12.8% | 1.1% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,929.3 Cr | -0.3% | -2.1% | 24.5% | Stock Analytics |
MARKSANS PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MARKSANS PHARMA | -4.8% |
-21% |
64.4% |
SENSEX | 0.3% |
-1.8% |
8.6% |
You may also like the below Video Courses